OptimizeRx (NASDAQ:OPRX) Given New $16.00 Price Target at Stifel Nicolaus

OptimizeRx (NASDAQ:OPRX) had its target price boosted by analysts at Stifel Nicolaus from $12.50 to $16.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 3.63% from the stock’s previous close.

OPRX has been the subject of several other research reports. B. Riley restated a “buy” rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Wall Street Zen upgraded OptimizeRx from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Roth Capital reiterated a “buy” rating on shares of OptimizeRx in a report on Tuesday, May 13th. Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, JMP Securities increased their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.81.

OptimizeRx Trading Up 4.6%

Shares of NASDAQ:OPRX opened at $15.44 on Monday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $15.63. The business has a 50 day moving average of $10.26 and a two-hundred day moving average of $7.39. The company has a market capitalization of $285.56 million, a PE ratio of -11.61 and a beta of 1.34.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.19. The firm had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. As a group, analysts forecast that OptimizeRx will post -0.33 EPS for the current year.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of OptimizeRx stock in a transaction dated Friday, March 14th. The shares were acquired at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares of the company’s stock, valued at $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On OptimizeRx

Several large investors have recently added to or reduced their stakes in the business. Whetstone Capital Advisors LLC lifted its holdings in OptimizeRx by 11.7% during the 1st quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company’s stock worth $13,062,000 after buying an additional 157,880 shares in the last quarter. Royce & Associates LP purchased a new stake in shares of OptimizeRx during the fourth quarter worth $5,198,000. Blair William & Co. IL raised its stake in shares of OptimizeRx by 4.9% in the first quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock valued at $5,465,000 after acquiring an additional 29,648 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of OptimizeRx by 57.8% in the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock valued at $2,887,000 after acquiring an additional 217,676 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new position in OptimizeRx in the first quarter valued at $4,114,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.